Suven Life Sciences Limited released its earnings results on Nov 11, 2025. The company reported -₹3.48 earnings per share for the quarter, missing the consensus estimate of N/A by -₹3.48.

Is Suven Life Sciences Limited overvalued?

According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Life Sciences Limited pay dividends?

Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here

What is Suven Life Sciences Limited’s EPS estimate?

Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Suven Life Sciences Limited have?

Suven Life Sciences Limited has 227,474,210 shares outstanding.

What happened to Suven Life Sciences Limited’s price movement after its last earnings report?

Suven Life Sciences Limited reported an EPS of -₹3.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.645%.

Which hedge fund is a major shareholder of Suven Life Sciences Limited?

Currently, no hedge funds are holding shares in IN:SUVEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Life Sciences Limited

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.